EX-23.1 3 a2022ex231accountingfirmco.htm EX-23.1

                                             Exhibit 23.1

Consent of Independent Registered Public Accounting Firm

We consent to the incorporation by reference in the following Registration Statements:

(1)Form S-3 Nos. 333-266926, 333-251161, 333-200453, 333-192749, 333-182330, 333-163479, 333-152171, 333-149981, 333-149980, 333-134126, and 333-108926 of CTI BioPharma Corp., and

(2)Form S-8 Nos. 333-265655, 333-257174, 333-239311, 333-231708, 333-225116, 333-218947, 333-218946, 333-211006, 333-207177, 333-207176, 333-196510, 333-189611, 333-184004, 333-178158, 333-170044, 333-162955, 333-158260, 333-152168, 333-146624 and 333-257174 pertaining to equity and option plans of CTI BioPharma Corp.

of our report dated March 6, 2023, with respect to the financial statements of CTI BioPharma Corp. included in this Annual Report (Form 10-K) of CTI BioPharma Corp. for the year ended December 31, 2022.

/s/ Ernst & Young LLP

Seattle, Washington                        

March 6, 2023